title: Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.
abstract: Single nucleotide polymorphisms near the interleukin 28B (IL-28B) gene have been identified as strong predictors of both spontaneous or Peg-interferon (Peg-IFN) and ribavirin (RBV) induced clearance of hepatitis C virus (HCV). Several studies have shown that, in patients with genotype 1 (GT-1), rs12979860 C/C and rs8099917 T/T substitutions are associated with a more than twofold increase in sustained virological response rate to Peg-IFN and RBV treatment. Although new treatment regimens based on combination of DAA with or without IFN are in the approval phase, until combination regimens with a backbone of Peg-IFN will be used, we can expect that IL28B holds its importance. The clinical relevance of IL28B genotyping in treatment of patients infected with HCV genotype 2 (GT-2) and 3 (GT-3) remains controversial. Therefore, after a careful examination of the available literature, we analyzed the impact of IL28B in GT-2 and -3. Simple size of the studies and GT-2 and GT-3 proportion were discussed. An algorithm for the practical use of IL28B in these patients was suggested at the aim of optimizing treatment.
authors.affiliation: Alessandra Mangia, Leonardo Mottola, Rosanna Santoro, Liver Unit-IRCCS, "Casa Sollievo della Sofferenza", San Giovanni Rotondo, 71013 FG, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mangia
authors.affiliation: Alessandra Mangia, Leonardo Mottola, Rosanna Santoro, Liver Unit-IRCCS, "Casa Sollievo della Sofferenza", San Giovanni Rotondo, 71013 FG, Italy.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Mottola
authors.affiliation: Alessandra Mangia, Leonardo Mottola, Rosanna Santoro, Liver Unit-IRCCS, "Casa Sollievo della Sofferenza", San Giovanni Rotondo, 71013 FG, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Santoro
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics* / Q000276:immunology; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda
keywords: Genotype 3; Hepatitis C virus; Interleukin 28B; Liver cirrhosis